Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Stock Has Consensus Price Target of $17.67 According to Brokerages

Key Points

• Aurinia Pharmaceuticals has a “Moderate Buy” consensus rating from six analysts, with an average 12-month price target of $17.67. Ratings include three holds, two buys, and one strong buy.
• AUPH opened at $16.44, with a market capitalization of approximately $2.19 billion and a 12-month trading range of $10.34 to $19.25. In its latest quarter, the company reported EPS of $0.28, exceeding estimates of $0.24, but revenue of $58.57 million fell short of the $80.45 million forecast.
• Institutional ownership stands at 36.83%, with BlackRock and Allianz Asset Management among firms that recently acquired stakes; other large investors, including Renaissance Technologies and Janus Henderson, increased their holdings.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP has been given an average recommendation of "Moderate Buy" by the six ratings firms that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $17.67.

Several research firms have weighed in on AUPH. Zacks Research lowered Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 21st. Wall Street Zen lowered shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Royal Bank Of Canada increased their price objective on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a "sector perform" rating in a research note on Friday, August 7th. Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 26th. Finally, Bloom Burton raised shares of Aurinia Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 20th.

Aurinia Pharmaceuticals Price Performance

AUPH stock opened at $16.44 on Monday. The firm has a 50 day moving average of $15.93 and a 200-day moving average of $15.77. The company has a market cap of $2.19 billion, a price-to-earnings ratio of 7.18 and a beta of 1.40. The company has a current ratio of 5.42, a quick ratio of 4.97 and a debt-to-equity ratio of 0.07. Aurinia Pharmaceuticals has a 12-month low of $10.34 and a 12-month high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.04. The business had revenue of $58.57 million for the quarter, compared to analysts' expectations of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. As a group, equities analysts expect that Aurinia Pharmaceuticals will post 0.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Aurinia Pharmaceuticals during the 2nd quarter valued at $139,037,000. Renaissance Technologies LLC increased its position in Aurinia Pharmaceuticals by 4.6% during the first quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company's stock worth $24,658,000 after buying an additional 73,700 shares in the last quarter. Allianz Asset Management GmbH acquired a new position in shares of Aurinia Pharmaceuticals in the second quarter worth $14,284,000. Janus Henderson Group PLC raised its holdings in shares of Aurinia Pharmaceuticals by 9.7% in the first quarter. Janus Henderson Group PLC now owns 757,435 shares of the biotechnology company's stock worth $11,225,000 after acquiring an additional 66,806 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Aurinia Pharmaceuticals by 48.5% in the fourth quarter. BNP Paribas Financial Markets now owns 625,684 shares of the biotechnology company's stock worth $9,980,000 after acquiring an additional 204,326 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc NASDAQ: AUPH is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's primary product is Lupkynis (voclosporin), an oral calcineurin inhibitor approved for use in combination with background immunosuppressive therapy to treat adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Lupkynis is designed to help control the underlying immune response associated with lupus nephritis and reduce the risk of progressive kidney damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.